Ethan Basch, MD, MSc

Dr. Basch is a medical oncologist and health services researcher.  His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research. He is also an Associate Editor of the Journal of the American Medical Association (JAMA).

He  is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He led the National Cancer Institute's initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.

Honors and Awards

Elected to Board of Directors

2019, American Society of Clinical Oncology (ASCO)

Ware/Tarlov Career Achievement Prize in Patient-Reported Outcomes Measures

2017, Health Assessment Labs

Appointee, Board of Scientific Advisors

2012, National Cancer Institute

Board of Directors

2011, International Society for Quality of Life Research

Education

BA, Literature, Brown University, 1989

MPhil, Literature, Oxford University, 1991

MD, Medicine, Harvard Medical School, 1998

MSc, Epidemiology, Harvard School of Public Health, 2005